CLDX Stock Recent News
CLDX LATEST HEADLINES
Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Proof of concept has been established in using Barzolvolimab in treating Chronic spontaneous urticaria and Chronic inducible urticaria patients in phase 1b studies. One phase 2 study with Barzolvolimab treating Chronic spontaneous urticaria patients has been initiated with second phase 2 study in Chronic inducible urticaria expected to start 2nd half of 2022.
Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Celldex Therapeutics Inc's (NASDAQ: CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four patient adverse events on the generally transient, asymptomatic, and mild.
Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.
Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.
HAMPTON, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference in New York City on Wednesday, June 8, 2022 at 8:30 a.m. ET.
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.
Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?